Key Takeaway: The SHIMMER study is an ongoing Phase 2 signal-finding trial evaluating CT1812 for mild-to-moderate dementia with Lewy bodies (DLB). Preliminary baseline data and insights were shared by researchers at the Clinical Trials on Alzheimer's Disease (CTAD) conference in Madrid, Spain. The study aims to assess the efficacy of CT1812 in this patient population.
Price reaction · baseline $0.4721 (2024-10-31 close) · hit pre-market · 2 other CGTX headline(s) in the window, move may be shared
day 0 close
-0.3%
Market Sentiment Analysis
POSITIVE FACTORS
The study is ongoing, indicating progress in research.
CT1812 is being investigated for its potential in treating DLB.
The presentation at a notable conference highlights its significance.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Full Press Release Details
Galvin JE, Tolea MI, Iaci JF, et al. SHIMMER: Baseline Data and Early Lessons from the Ongoing Phase 2 Signal-finding Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies (DLB). Poster presented at Clinical Trials on Alzheimer’s Disease (CTAD) ; Madrid, Spain.
Frequently Asked Questions
What is the SHIMMER study about?
The SHIMMER study is an ongoing Phase 2 trial evaluating CT1812 for mild-to-moderate dementia with Lewy bodies.
Where was the SHIMMER study presented?
The findings were presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference in Madrid, Spain.
What are the goals of the SHIMMER study?
The study aims to assess the efficacy of CT1812 in treating dementia with Lewy bodies.
Who are the researchers involved in the SHIMMER study?
The study involves researchers including Galvin JE, Tolea MI, and Iaci JF.